Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome

Ishwarlal Jialal, Sridevi Devaraj, Harmeet Kaur, Beverley Adams-Huet, Andrew A. Bremer

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Context: Adipose tissue dysregulation causing aberrant adipokine secretion contributes toward the proinflammatory state of metabolic syndrome (MetS). However, there are scant data on the role of novel adipokines in MetS. Objective: The aim of this study was to determine the levels of circulating and adipose tissue-secreted adipokines, chemerin, omentin-1, resistin, and visfatin in nascent MetS patients without diabetes or cardiovascular disease and to determine their relation with features of MetS. Design and Setting: Subjects with MetS and gender- and age-matched controls were recruited after informed consent. Fasting blood samples and gluteal subcutaneous adipose tissue (SAT) biopsies were obtained. Main Outcome: SAT-secreted and plasma levels of chemerin, omentin-1, resistin, and visfatin were quantitated. Results: There was significantly higher circulating as well as SAT-released chemerin in nascent MetS compared to controls, which persisted after adjustment for body mass index, waist circumference, and age. Also, both SAT-released and plasma levels of omentin-1 were significantly lower in MetS compared to controls, and the significant differences persisted after adjustment for age, body mass index, or waist circumference. No significant differences were observed in the levels of circulating visfatin as well as SAT-secreted resistin and visfatin. Chemerin correlated significantly with high-sensitivity C-reactive protein, homeostasis model of assessment for insulin resistance, triglycerides, and blood pressure, and inversely with omentin and high-density lipoprotein cholesterol. Omentin correlated significantly with high-density lipoprotein cholesterol and inversely with glucose and triglycerides. Conclusions: We make the novel observation of abnormal circulating and gluteal SAT-secreted chemerin and omentin-1 levels in nascent MetS, which could confer a higher risk for diabetes and cardiovascular disease.

Original languageEnglish (US)
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Adipose Tissue
Subcutaneous Fat
Nicotinamide Phosphoribosyltransferase
Tissue
Plasmas
Resistin
Adipokines
Waist Circumference
Medical problems
HDL Cholesterol
Triglycerides
Body Mass Index
Cardiovascular Diseases
Biopsy
Blood pressure
Informed Consent
C-Reactive Protein
Insulin Resistance
Fasting
Homeostasis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. / Jialal, Ishwarlal; Devaraj, Sridevi; Kaur, Harmeet; Adams-Huet, Beverley; Bremer, Andrew A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 3, 03.2013.

Research output: Contribution to journalArticle

Jialal, Ishwarlal ; Devaraj, Sridevi ; Kaur, Harmeet ; Adams-Huet, Beverley ; Bremer, Andrew A. / Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 3.
@article{90f20aa321a448c8997a6cbead753583,
title = "Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome",
abstract = "Context: Adipose tissue dysregulation causing aberrant adipokine secretion contributes toward the proinflammatory state of metabolic syndrome (MetS). However, there are scant data on the role of novel adipokines in MetS. Objective: The aim of this study was to determine the levels of circulating and adipose tissue-secreted adipokines, chemerin, omentin-1, resistin, and visfatin in nascent MetS patients without diabetes or cardiovascular disease and to determine their relation with features of MetS. Design and Setting: Subjects with MetS and gender- and age-matched controls were recruited after informed consent. Fasting blood samples and gluteal subcutaneous adipose tissue (SAT) biopsies were obtained. Main Outcome: SAT-secreted and plasma levels of chemerin, omentin-1, resistin, and visfatin were quantitated. Results: There was significantly higher circulating as well as SAT-released chemerin in nascent MetS compared to controls, which persisted after adjustment for body mass index, waist circumference, and age. Also, both SAT-released and plasma levels of omentin-1 were significantly lower in MetS compared to controls, and the significant differences persisted after adjustment for age, body mass index, or waist circumference. No significant differences were observed in the levels of circulating visfatin as well as SAT-secreted resistin and visfatin. Chemerin correlated significantly with high-sensitivity C-reactive protein, homeostasis model of assessment for insulin resistance, triglycerides, and blood pressure, and inversely with omentin and high-density lipoprotein cholesterol. Omentin correlated significantly with high-density lipoprotein cholesterol and inversely with glucose and triglycerides. Conclusions: We make the novel observation of abnormal circulating and gluteal SAT-secreted chemerin and omentin-1 levels in nascent MetS, which could confer a higher risk for diabetes and cardiovascular disease.",
author = "Ishwarlal Jialal and Sridevi Devaraj and Harmeet Kaur and Beverley Adams-Huet and Bremer, {Andrew A.}",
year = "2013",
month = "3",
doi = "10.1210/jc.2012-3673",
language = "English (US)",
volume = "98",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome

AU - Jialal, Ishwarlal

AU - Devaraj, Sridevi

AU - Kaur, Harmeet

AU - Adams-Huet, Beverley

AU - Bremer, Andrew A.

PY - 2013/3

Y1 - 2013/3

N2 - Context: Adipose tissue dysregulation causing aberrant adipokine secretion contributes toward the proinflammatory state of metabolic syndrome (MetS). However, there are scant data on the role of novel adipokines in MetS. Objective: The aim of this study was to determine the levels of circulating and adipose tissue-secreted adipokines, chemerin, omentin-1, resistin, and visfatin in nascent MetS patients without diabetes or cardiovascular disease and to determine their relation with features of MetS. Design and Setting: Subjects with MetS and gender- and age-matched controls were recruited after informed consent. Fasting blood samples and gluteal subcutaneous adipose tissue (SAT) biopsies were obtained. Main Outcome: SAT-secreted and plasma levels of chemerin, omentin-1, resistin, and visfatin were quantitated. Results: There was significantly higher circulating as well as SAT-released chemerin in nascent MetS compared to controls, which persisted after adjustment for body mass index, waist circumference, and age. Also, both SAT-released and plasma levels of omentin-1 were significantly lower in MetS compared to controls, and the significant differences persisted after adjustment for age, body mass index, or waist circumference. No significant differences were observed in the levels of circulating visfatin as well as SAT-secreted resistin and visfatin. Chemerin correlated significantly with high-sensitivity C-reactive protein, homeostasis model of assessment for insulin resistance, triglycerides, and blood pressure, and inversely with omentin and high-density lipoprotein cholesterol. Omentin correlated significantly with high-density lipoprotein cholesterol and inversely with glucose and triglycerides. Conclusions: We make the novel observation of abnormal circulating and gluteal SAT-secreted chemerin and omentin-1 levels in nascent MetS, which could confer a higher risk for diabetes and cardiovascular disease.

AB - Context: Adipose tissue dysregulation causing aberrant adipokine secretion contributes toward the proinflammatory state of metabolic syndrome (MetS). However, there are scant data on the role of novel adipokines in MetS. Objective: The aim of this study was to determine the levels of circulating and adipose tissue-secreted adipokines, chemerin, omentin-1, resistin, and visfatin in nascent MetS patients without diabetes or cardiovascular disease and to determine their relation with features of MetS. Design and Setting: Subjects with MetS and gender- and age-matched controls were recruited after informed consent. Fasting blood samples and gluteal subcutaneous adipose tissue (SAT) biopsies were obtained. Main Outcome: SAT-secreted and plasma levels of chemerin, omentin-1, resistin, and visfatin were quantitated. Results: There was significantly higher circulating as well as SAT-released chemerin in nascent MetS compared to controls, which persisted after adjustment for body mass index, waist circumference, and age. Also, both SAT-released and plasma levels of omentin-1 were significantly lower in MetS compared to controls, and the significant differences persisted after adjustment for age, body mass index, or waist circumference. No significant differences were observed in the levels of circulating visfatin as well as SAT-secreted resistin and visfatin. Chemerin correlated significantly with high-sensitivity C-reactive protein, homeostasis model of assessment for insulin resistance, triglycerides, and blood pressure, and inversely with omentin and high-density lipoprotein cholesterol. Omentin correlated significantly with high-density lipoprotein cholesterol and inversely with glucose and triglycerides. Conclusions: We make the novel observation of abnormal circulating and gluteal SAT-secreted chemerin and omentin-1 levels in nascent MetS, which could confer a higher risk for diabetes and cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=84874875635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874875635&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-3673

DO - 10.1210/jc.2012-3673

M3 - Article

C2 - 23303213

AN - SCOPUS:84874875635

VL - 98

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -